CITCO

立即咨询

CITCO

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

338404-52-7

包装与价格：

包装	价格(元)
5mg	电议
10mg	电议
25mg	电议

产品介绍

化学性质

Physical Appearance	A crystalline solid
Storage	Desiccate at -20°C
M.Wt	436.74
Cas No.	338404-52-7
Formula	C₁₉H₁₂Cl₃N₃OS
Solubility	Soluble in DMSO
Chemical Name	(E)-6-(4-chlorophenyl)imidazo[2,1-b]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl) oxime
Canonical SMILES	ClC1=CC=C(C=C1)C2=C(/C=N/OCC(C=C3Cl)=CC=C3Cl)N4C(SC=C4)=N2
运输条件	蓝冰运输或根据您的需求运输。
一般建议	为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

CITCO, an imidazothiazole derivative, is a selective agonist of human CAR, with an EC50 value of 49 nM and > 50-fold selectivity to CAR over pregnane X receptor (PXR), and no activity on other nuclear receptors. Upon activation with specific agonists, CAR translocates into the nucleus and binds to the response elements as monomers or CAR/RXR heterodimers. The CAR functions as a xenobiotic receptor, involved in detoxification and clearance of toxic substances from the liver. In addition, activation with selective CAR agonists such as CITCO has also been shown to inhibit growth and expansion of brain tumor stem cells.

Reference:

1. Chakraborty S, Kanakasabai S, Bright JJ. Constitutive androstane receptor agonist CITCO inhibits growth and expansion of brain tumour stem cells. British Journal of Cancer, 2011, 104(3): 448-459.

试验操作

Cell experiment:[1]
Cell lines	T98G, U87MG, DB29 and DB33 glioma cells
Reaction Conditions	2.5 ~ 10 μM CITCO for 48 h incubation
Applications	The brain tumor stem cells (BTSCs) from T98G and U87MG cultured in the absence of CITCO showed 6.8 and 11% Annexin V-positive cells that increased to 62 and 68% following addition of 10 μM CITCO, respectively. Moreover, BTSCs from DB29 and DB33 gliomas showed 3 and 0.5% Annexin V-positive cells that increased to 24 and 41% following treatment with 10 μM CITCO, respectively. CITCO dose-dependently induced apoptosis in BTSCs in culture, but not in normal astrocytes.
Animal experiment:[1]
Animal models	Nude mice subcutaneously injected with U87MG–BTSCs
Dosage form	25 or 100 μg Intraperitoneal injection; on days 22, 24, 26, 30 and 36
Applications	CITCO at the dose of 25 μg resulted in a significant decrease in tumour growth, which further decreased to an undetectable level after treatment with 100 μg CITCO.
Note	The technical data provided above is for reference only.
	References: 1. Chakraborty S, Kanakasabai S, Bright JJ. Constitutive androstane receptor agonist CITCO inhibits growth and expansion of brain tumour stem cells. British Journal of Cancer, 2011, 104(3): 448-459.